

| Catalog No. | MS870013 |
|---|---|
| Description |
Anti-Mouse PD1 antibody(RMP1-14) [RMP1-14] (MS870013) is a rat monoclonal antibody detecting Mouse PD1 in Neutralization. Suitable for Mouse.
|
| Species reactivity | Mouse |
| Applications | Neutralization |
| Host species | Rat |
| Isotype | IgG2a, kappa |
| Clone ID | RMP1-14 |
| Clonality | Monoclonal |
| Target | CD279/PD-1 |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | Q02242 |
| RRID | Anti-Mouse PD1 antibody(RMP1-14) (abinScience Cat# MS870013, RRID:AB_3729831) |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | Programmed cell death protein 1, Protein PD-1, hPD-1, CD279, PDCD1 |
| Background | Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Nishimura, H. et al. (1999) Immunity 11, 141-51. PMID: 10485649 2. Nishimura, H. et al. (2001) Science (New York, N.Y.) 291, 319-22. PMID: 11209085 3. Okazaki, T. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 13866-71. PMID: 11698646 4. Okazaki, T. et al. (2011) The Journal of experimental medicine 208, 395-407. PMID: 21300912 5. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 6. Latchman, Y. et al. (2001) Nature immunology 2, 261-8. PMID: 11224527 7. Lin, DY. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 3011-6. PMID: 18287011 8. Lázár-Molnár, E. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 10483-8. PMID: 18641123 9. Yokosuka, T. et al. (2012) The Journal of experimental medicine 209, 1201-17. PMID: 22641383 |
| Note | For research use only. |

SDS-PAGE for Anti-Mouse PD1 antibody(RMP1-14)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский